688065 凯赛生物
已收盘 06-03 15:00:00
资讯
新帖
简况
每周股票复盘：凯赛生物（688065）2025年营收增11.40%
证券之星 · 05-24
每周股票复盘：凯赛生物（688065）2025年营收增11.40%
凯赛生物（688065）披露2025年度持续督导工作现场检查报告，5月21日股价下跌4.03%
证券之星 · 05-21
凯赛生物（688065）披露2025年度持续督导工作现场检查报告，5月21日股价下跌4.03%
凯赛生物（688065）发布2025年度持续督导跟踪报告，5月20日股价上涨1.78%
证券之星 · 05-20
凯赛生物（688065）发布2025年度持续督导跟踪报告，5月20日股价上涨1.78%
凯赛生物跌2.38% 2020年上市即巅峰2度募资合计115亿
中金财经 · 05-15
凯赛生物跌2.38% 2020年上市即巅峰2度募资合计115亿
年收破30亿 凯赛生物(688065.SH)是否真稀缺标的？
智通财经 · 05-09
年收破30亿 凯赛生物(688065.SH)是否真稀缺标的？
股市必读：凯赛生物一季报 - 第一季度单季净利润同比增长21.01%
证券之星 · 05-06
股市必读：凯赛生物一季报 - 第一季度单季净利润同比增长21.01%
每周股票复盘：凯赛生物（688065）现折价21.99%大宗交易
证券之星 · 05-02
每周股票复盘：凯赛生物（688065）现折价21.99%大宗交易
凯赛生物（688065）2026年一季报简析：营收净利润同比双双增长，三费占比上升明显
证券之星 · 05-01
凯赛生物（688065）2026年一季报简析：营收净利润同比双双增长，三费占比上升明显
图解凯赛生物一季报：第一季度单季净利润同比增长21.01%
证券之星 · 04-30
图解凯赛生物一季报：第一季度单季净利润同比增长21.01%
4月29日凯赛生物现1笔折价21.99%的大宗交易 合计成交499.02万元
证券之星 · 04-29
4月29日凯赛生物现1笔折价21.99%的大宗交易 合计成交499.02万元
每周股票复盘：凯赛生物（688065）股东户数增28.48%，2025年净利升14.68%
证券之星 · 04-26
每周股票复盘：凯赛生物（688065）股东户数增28.48%，2025年净利升14.68%
凯赛生物跌3.56% 2020年上市即巅峰2度募资合计115亿
中金财经 · 04-24
凯赛生物跌3.56% 2020年上市即巅峰2度募资合计115亿
图解凯赛生物年报：第四季度单季净利润同比下降23.46%
证券之星 · 04-24
图解凯赛生物年报：第四季度单季净利润同比下降23.46%
每周股票复盘：凯赛生物（688065）现折价23.05%大宗交易
证券之星 · 04-12
每周股票复盘：凯赛生物（688065）现折价23.05%大宗交易
凯赛生物跌2.79% 2020年上市即巅峰2度募资合计115亿
中金财经 · 04-09
凯赛生物跌2.79% 2020年上市即巅峰2度募资合计115亿
4月8日凯赛生物现1笔折价23.05%的大宗交易 合计成交501.99万元
证券之星 · 04-08
4月8日凯赛生物现1笔折价23.05%的大宗交易 合计成交501.99万元
股市必读：3月23日凯赛生物现1笔折价18.81%的大宗交易 合计成交497.84万元
证券之星 · 03-24
股市必读：3月23日凯赛生物现1笔折价18.81%的大宗交易 合计成交497.84万元
凯赛生物新注册《多元数据智能建模在线预测系统V2.0.0》项目的软件著作权
证券之星 · 03-22
凯赛生物新注册《多元数据智能建模在线预测系统V2.0.0》项目的软件著作权
凯赛生物跌3.16% 2020年上市即巅峰2度募资合计115亿
中金财经 · 03-18
凯赛生物跌3.16% 2020年上市即巅峰2度募资合计115亿
凯赛生物跌3.99% 2020年上市即巅峰2度募资合计115亿
中金财经 · 03-17
凯赛生物跌3.99% 2020年上市即巅峰2度募资合计115亿
加载更多
公司概况
公司名称：
上海凯赛生物技术股份有限公司
所属行业：
化学纤维制造业
上市日期：
2020-08-12
主营业务：
上海凯赛生物技术股份有限公司的主营业务是新型生物基材料的研发、生产及销售。公司的主要产品是系列生物法长链二元酸（DC10-DC18）、生物基戊二胺、系列生物基聚酰胺、生物基连续纤维热塑型复合材料（Bio-PPACFRT）。截至报告期末，公司拥有434项发明专利在内的562项专利，被认定为“国家企业技术中心”、“国家级第三批专精特新‘小巨人’企业”、“国家知识产权局优势企业”、“国家绿色工厂”、“国家制造业单项冠军企业”。
发行价格：
133.45
{"stockData":{"symbol":"688065","market":"SH","secType":"STK","nameCN":"凯赛生物","latestPrice":40.68,"timestamp":1780470000000,"preClose":40.67,"halted":0,"volume":5314904,"delay":0,"changeRate":0.0002,"floatShares":583000000,"shares":721000000,"eps":0.8173,"marketStatus":"已收盘","change":0.01,"latestTime":"06-03 15:00:00","open":40.8,"high":41.64,"low":39.99,"amount":217000000,"amplitude":0.0406,"askPrice":40.89,"askSize":2,"bidPrice":40.68,"bidSize":96,"shortable":0,"etf":0,"ttmEps":0.8173,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780536600000},"marketStatusCode":5,"adr":0,"adjPreClose":40.67,"symbolType":"stock_kcb","openAndCloseTimeList":[[1780450200000,1780457400000],[1780462800000,1780470000000]],"highLimit":44.74,"lowLimit":36.6,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":721289794,"isCdr":false,"pbRate":1.64,"roa":"--","peRate":49.773645,"roe":"0.93%","epsLYR":0.82,"committee":0.834297,"marketValue":29342000000,"turnoverRate":0.0091,"status":0,"afterMarket":{"amount":0,"volume":0,"close":40.68,"buyVolume":2158,"sellVolume":0,"time":1780472038866,"indexStatus":"已收盘 06-03 15:30:00","preClose":40.67},"floatMarketCap":23732000000},"requestUrl":"/m/hq/s/688065","defaultTab":"news","newsList":[{"id":"2637486373","title":"每周股票复盘：凯赛生物（688065）2025年营收增11.40%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637486373","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637486373?lang=zh_cn&edition=full","pubTime":"2026-05-24 02:41","pubTimestamp":1779561669,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘，凯赛生物报收于43.46元，较上周的45.88元下跌5.27%。本周，凯赛生物5月21日盘中最高价报46.07元。中信证券作为保荐人，发布凯赛生物2025年度持续督导跟踪报告，报告期内公司实现营业收入329,505.19万元，同比增长11.40%；净利润56,072.00万元，同比增长14.68%。中信证券对凯赛生物开展2025年度持续督导工作现场检查，涵盖公司治理、信息披露、募集资金使用、关联交易、对外担保、重大对外投资等方面。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000663.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637332348","title":"凯赛生物（688065）披露2025年度持续督导工作现场检查报告，5月21日股价下跌4.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637332348","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637332348?lang=zh_cn&edition=full","pubTime":"2026-05-21 22:22","pubTimestamp":1779373341,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，凯赛生物报收于43.29元，较前一交易日下跌4.03%，最新总市值为312.25亿元。近日，中信证券股份有限公司发布《关于上海凯赛生物技术股份有限公司2025年度持续督导工作现场检查报告》。公告显示，中信证券作为保荐人，对凯赛生物2025年度持续督导期间的规范运作情况进行了现场检查，涵盖公司治理、信息披露、募集资金使用、关联交易、对外担保、重大对外投资等方面。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100044449.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636772845","title":"凯赛生物（688065）发布2025年度持续督导跟踪报告，5月20日股价上涨1.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636772845","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636772845?lang=zh_cn&edition=full","pubTime":"2026-05-20 18:29","pubTimestamp":1779272953,"startTime":"0","endTime":"0","summary":"截至2026年5月20日收盘，凯赛生物报收于45.11元，较前一交易日上涨1.78%，最新总市值为325.37亿元。该股当日开盘43.97元，最高45.42元，最低43.61元，成交额达2.57亿元，换手率为0.99%。近日，中信证券股份有限公司发布《关于上海凯赛生物技术股份有限公司2025年度持续督导跟踪报告》。公告显示，报告期内，公司营业收入329,505.19万元，同比增长11.40%；净利润56,072.00万元，同比增长14.68%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000035742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635701969","title":"凯赛生物跌2.38% 2020年上市即巅峰2度募资合计115亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2635701969","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635701969?lang=zh_cn&edition=full","pubTime":"2026-05-15 15:57","pubTimestamp":1778831820,"startTime":"0","endTime":"0","summary":"中国经济网北京5月15日讯 凯赛生物 今日收报45.88元，跌幅2.38%。 凯赛生物于2020年8月12日在上交所科创板上市，公开发行股份总数为4,166.8198万股，占发行后股份总数的10.00%，发行价格为133.45元/股，保荐人为中信证券股份有限公司，保荐代表人为先卫国、黄艺彬。 上市首日，凯赛生物盘中最高价198元，为该股上市以来最高价。 凯赛生物首次公开发行股票募集资金总额556,062.10万元，募集资金净额为527,999.38万元。 凯赛生物上述2次募集资金合计114.87亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260515/32227644.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634049750","title":"年收破30亿 凯赛生物(688065.SH)是否真稀缺标的？","url":"https://stock-news.laohu8.com/highlight/detail?id=2634049750","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634049750?lang=zh_cn&edition=full","pubTime":"2026-05-09 15:58","pubTimestamp":1778313487,"startTime":"0","endTime":"0","summary":"随着2026年4月年报披露季结束，在生物科技赛道共计134家上市公司中，以收入规模增速、净利润增速、毛利率增速等指标均为正增长为筛选标准，凯赛生物成为率先用三年时间验证产业化平台模式的企业，实现了从合成生物学概念兴起到生物制造被定位为国家未来支柱产业进程中的阶段性突破。其中在3家公司总资产均处在增长阶段的背景下，仅凯赛生物营收规模突破30亿，也只有凯赛生物连续三年毛利率稳步提升。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439863.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633921823","title":"股市必读：凯赛生物一季报 - 第一季度单季净利润同比增长21.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633921823","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633921823?lang=zh_cn&edition=full","pubTime":"2026-05-06 04:23","pubTimestamp":1778012589,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，凯赛生物报收于48.11元，上涨0.78%，换手率1.37%，成交量7.97万手，成交额3.89亿元。来自业绩披露要点：2026年一季度归母净利润同比增长21.01%，达1.66亿元。股本股东变化股东户数变动近日凯赛生物披露，截至2026年3月31日公司股东户数为1.85万户，较12月31日增加4106.0户，增幅为28.48%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600003512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632401846","title":"每周股票复盘：凯赛生物（688065）现折价21.99%大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2632401846","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632401846?lang=zh_cn&edition=full","pubTime":"2026-05-02 04:52","pubTimestamp":1777668730,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，凯赛生物报收于48.11元，较上周的47.42元上涨1.46%。本周，凯赛生物4月30日盘中最高价报49.96元。业绩披露要点：凯赛生物2026年一季度归母净利润1.66亿元，同比增长21.01%。交易信息汇总4月29日凯赛生物现1笔折价21.99%的大宗交易，合计成交499.02万元。股本股东变化股东户数变动近日凯赛生物披露，截至2026年3月31日公司股东户数为1.85万户，较12月31日增加4106.0户，增幅为28.48%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200002868.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632266049","title":"凯赛生物（688065）2026年一季报简析：营收净利润同比双双增长，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2632266049","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632266049?lang=zh_cn&edition=full","pubTime":"2026-05-01 06:45","pubTimestamp":1777589148,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期凯赛生物发布2026年一季报。截至本报告期末，公司营业总收入8.75亿元，同比上升12.73%，归母净利润1.66亿元，同比上升21.01%。本报告期凯赛生物三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达131.97%。然而去年的净利率为16.07%，算上全部成本后，公司产品或服务的附加值高。持有凯赛生物最多的基金为科创新材料ETF博时，目前规模为2.02亿元，最新净值1.0215，较上一交易日下跌0.44%，近一年上涨75.2%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050100007130.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631528796","title":"图解凯赛生物一季报：第一季度单季净利润同比增长21.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631528796","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631528796?lang=zh_cn&edition=full","pubTime":"2026-04-30 03:32","pubTimestamp":1777491175,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物2026年一季报显示，一季度公司主营收入8.75亿元，同比上升12.73%；归母净利润1.66亿元，同比上升21.01%；扣非净利润1.48亿元，同比上升9.07%；负债率12.51%，投资收益-376.03万元，财务费用2650.62万元，毛利率36.04%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026043000009732.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631591001","title":"4月29日凯赛生物现1笔折价21.99%的大宗交易 合计成交499.02万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631591001","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631591001?lang=zh_cn&edition=full","pubTime":"2026-04-29 18:17","pubTimestamp":1777457844,"startTime":"0","endTime":"0","summary":"证券之星消息，4月29日凯赛生物发生大宗交易，交易数据如下：大宗交易成交价格37.24元，相对当日收盘价折价21.99%，成交13.4万股，成交金额499.02万元，买方营业部为长城证券股份有限公司重庆新南路证券营业部，卖方营业部为长城证券股份有限公司重庆新南路证券营业部。近三个月该股共发生5笔大宗交易，合计成交7180.0手，折价成交5笔。截至2026年4月29日收盘，凯赛生物报收于47.74元，上涨2.56%，换手率0.85%，成交量4.98万手，成交额2.38亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900058160.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630019418","title":"每周股票复盘：凯赛生物（688065）股东户数增28.48%，2025年净利升14.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630019418","media":"证券之星","labels":["shareholding","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630019418?lang=zh_cn&edition=full","pubTime":"2026-04-26 02:32","pubTimestamp":1777141932,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，凯赛生物报收于47.42元，较上周的48.01元下跌1.23%。本周，凯赛生物4月23日盘中最高价报49.96元。凯赛生物当前最新总市值342.04亿元，在化学制品板块市值排名10/171，在两市A股市值排名623/5200。业绩披露要点：2025年归母净利润5.61亿元，同比上升14.68%。股本股东变化股东户数变动截至2026年3月31日，公司股东户数为1.85万户，较2025年12月31日增加4106.0户，增幅28.48%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600000885.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629811777","title":"凯赛生物跌3.56% 2020年上市即巅峰2度募资合计115亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2629811777","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629811777?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:19","pubTimestamp":1777022357,"startTime":"0","endTime":"0","summary":"中国经济网北京4月24日讯 凯赛生物 今日收报47.42元，跌幅3.56%。 凯赛生物于2020年8月12日在上交所科创板上市，公开发行股份总数为4,166.8198万股，占发行后股份总数的10.00%，发行价格为133.45元/股，保荐人为中信证券股份有限公司，保荐代表人为先卫国、黄艺彬。 上市首日，凯赛生物盘中最高价198元，为该股上市以来最高价。 凯赛生物首次公开发行股票募集资金总额556,062.10万元，募集资金净额为527,999.38万元。 凯赛生物上述2次募集资金合计114.87亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260424/32172069.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["IPOS","688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629548088","title":"图解凯赛生物年报：第四季度单季净利润同比下降23.46%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629548088","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629548088?lang=zh_cn&edition=full","pubTime":"2026-04-24 01:30","pubTimestamp":1776965439,"startTime":"0","endTime":"0","summary":"证券之星消息，凯赛生物2025年年报显示，当年度公司主营收入32.95亿元，同比上升11.4%；归母净利润5.61亿元，同比上升14.68%；扣非净利润5.21亿元，同比上升12.04%；其中2025年第四季度，公司单季度主营收入7.5亿元，同比上升0.97%；单季度归母净利润1.1亿元，同比下降23.46%；单季度扣非净利润9213.45万元，同比下降28.83%；负债率10.75%，投资收益140.17万元，财务费用-9886.77万元，毛利率34.22%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400003691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626122130","title":"每周股票复盘：凯赛生物（688065）现折价23.05%大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2626122130","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626122130?lang=zh_cn&edition=full","pubTime":"2026-04-12 01:59","pubTimestamp":1775930347,"startTime":"0","endTime":"0","summary":"截至2026年4月10日收盘，凯赛生物报收于48.8元，较上周的47.7元上涨2.31%。本周，凯赛生物4月8日盘中最高价报49.92元。4月7日盘中最低价报47.78元。凯赛生物当前最新总市值351.99亿元，在化学制品板块市值排名9/171，在两市A股市值排名585/5196。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041200000512.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626246907","title":"凯赛生物跌2.79% 2020年上市即巅峰2度募资合计115亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2626246907","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2626246907?lang=zh_cn&edition=full","pubTime":"2026-04-09 16:53","pubTimestamp":1775724797,"startTime":"0","endTime":"0","summary":"中国经济网北京4月9日讯 凯赛生物 今日收报48.41元，跌幅2.79%。 凯赛生物于2020年8月12日在上交所科创板上市，公开发行股份总数为4,166.8198万股，占发行后股份总数的10.00%，发行价格为133.45元/股，保荐人为中信证券股份有限公司，保荐代表人为先卫国、黄艺彬。 上市首日，凯赛生物盘中最高价198元，为该股上市以来最高价。 凯赛生物首次公开发行股票募集资金总额556,062.10万元，募集资金净额为527,999.38万元。 凯赛生物上述2次募集资金合计114.87亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260409/32133936.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688065","IPOS","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625917280","title":"4月8日凯赛生物现1笔折价23.05%的大宗交易 合计成交501.99万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2625917280","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625917280?lang=zh_cn&edition=full","pubTime":"2026-04-08 17:53","pubTimestamp":1775642003,"startTime":"0","endTime":"0","summary":"证券之星消息，4月8日凯赛生物发生大宗交易，交易数据如下：大宗交易成交价格38.32元，相对当日收盘价折价23.05%，成交13.1万股，成交金额501.99万元，买方营业部为长城证券股份有限公司重庆新南路证券营业部，卖方营业部为长城证券股份有限公司重庆新南路证券营业部。近三个月该股共发生4笔大宗交易，合计成交5840.0手，折价成交4笔。截至2026年4月8日收盘，凯赛生物报收于49.8元，上涨3.99%，换手率0.8%，成交量4.65万手，成交额2.3亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040800028184.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621833060","title":"股市必读：3月23日凯赛生物现1笔折价18.81%的大宗交易 合计成交497.84万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2621833060","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621833060?lang=zh_cn&edition=full","pubTime":"2026-03-24 01:17","pubTimestamp":1774286265,"startTime":"0","endTime":"0","summary":"截至2026年3月23日收盘，凯赛生物报收于48.28元，下跌1.47%，换手率1.25%，成交量7.28万手，成交额3.56亿元。交易信息汇总资金流向3月23日主力资金净流入3019.15万元，占总成交额8.49%；游资资金净流出1866.15万元，占总成交额5.25%；散户资金净流出1153.0万元，占总成交额3.24%。大宗交易3月23日凯赛生物现1笔折价18.81%的大宗交易，合计成交497.84万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032400001371.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621219796","title":"凯赛生物新注册《多元数据智能建模在线预测系统V2.0.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2621219796","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621219796?lang=zh_cn&edition=full","pubTime":"2026-03-22 02:15","pubTimestamp":1774116915,"startTime":"0","endTime":"0","summary":"证券之星消息，近日凯赛生物（688065）新注册了《多元数据智能建模在线预测系统V2.0.0》项目的软件著作权。今年以来凯赛生物新注册软件著作权1个。结合公司2025年中报财务数据，2025上半年公司在研发方面投入了1.23亿元，同比增23.13%。通过天眼查大数据分析，上海凯赛生物技术股份有限公司共对外投资了14家企业，参与招投标项目7次；财产线索方面有商标信息152条，专利信息755条，著作权信息11条；此外企业还拥有行政许可9个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000500.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0208","688065"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620342232","title":"凯赛生物跌3.16% 2020年上市即巅峰2度募资合计115亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2620342232","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620342232?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:16","pubTimestamp":1773828969,"startTime":"0","endTime":"0","summary":"中国经济网北京3月18日讯 凯赛生物 今日股价下跌，截至收盘报52.44元，跌幅3.16%。 上市首日，凯赛生物盘中最高价198元，为该股上市以来最高价。 凯赛生物首次公开发行股票募集资金总额556,062.10万元，募集资金净额为527,999.38万元。 凯赛生物上述2次募集资金合计114.87亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260318/32078742.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620601447","title":"凯赛生物跌3.99% 2020年上市即巅峰2度募资合计115亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2620601447","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620601447?lang=zh_cn&edition=full","pubTime":"2026-03-17 16:54","pubTimestamp":1773737673,"startTime":"0","endTime":"0","summary":"中国经济网北京3月17日讯 凯赛生物 今日股价下跌，截至收盘报54.15元，跌幅3.99%。 凯赛生物于2020年8月12日在上交所科创板上市，公开发行股份总数为4,166.8198万股，占发行后股份总数的10.00%，发行价格为133.45元/股，保荐人为中信证券股份有限公司，保荐代表人为先卫国、黄艺彬。 上市首日，凯赛生物盘中最高价198元，为该股上市以来最高价。 凯赛生物上述2次募集资金合计114.87亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260317/32074824.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688065","BK0208"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780505825590,"stockEarnings":[{"period":"1week","weight":-0.0259},{"period":"1month","weight":-0.1544},{"period":"3month","weight":-0.2132},{"period":"6month","weight":-0.1158},{"period":"1year","weight":-0.125},{"period":"ytd","weight":-0.1831}],"compareEarnings":[{"period":"1week","weight":-0.0024},{"period":"1month","weight":-0.0069},{"period":"3month","weight":-0.006},{"period":"6month","weight":0.0464},{"period":"1year","weight":0.2148},{"period":"ytd","weight":0.029}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海凯赛生物技术股份有限公司","boardCode":"AI0028","boardName":"化学纤维制造业","stockholders":"18523人(较上一季度增加28.48%)","perCapita":"31494股","listingDate":"2020-08-12","address":"上海市浦东新区中国(上海)自由贸易试验区蔡伦路1690号5幢4楼","registeredCapital":"72128万元","survey":" 上海凯赛生物技术股份有限公司的主营业务是新型生物基材料的研发、生产及销售。公司的主要产品是系列生物法长链二元酸（DC10-DC18）、生物基戊二胺、系列生物基聚酰胺、生物基连续纤维热塑型复合材料（Bio-PPACFRT）。截至报告期末，公司拥有434项发明专利在内的562项专利，被认定为“国家企业技术中心”、“国家级第三批专精特新‘小巨人’企业”、“国家知识产权局优势企业”、“国家绿色工厂”、“国家制造业单项冠军企业”。","listedPrice":133.45},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"凯赛生物,688065,凯赛生物股票,凯赛生物股票老虎,凯赛生物股票老虎国际,凯赛生物行情,凯赛生物股票行情,凯赛生物股价,凯赛生物股市,凯赛生物股票价格,凯赛生物股票交易,凯赛生物股票购买,凯赛生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"凯赛生物(688065)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供凯赛生物(688065)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}